Yoon Seong-tae, chairman of Huons Group, has returned to the management front line. It has been three years since Yoon resigned as CEO of Huons Global in 2022.
On the 28th, Huons Global, the holding company of Huons Group, held its regular shareholders' meeting and board meeting at its headquarters in Pangyo, Gyeonggi Province, and announced the approval of Yoon Seong-tae's appointment as CEO.
It was reported that this was approved on the 28th. As a result, Huons Global has established a dual CEO system with Yoon Seong-tae and Song Soo-young.
Huons Group aims to focus on overcoming economic crises, nurturing future core businesses, expanding into global markets, and securing competitive new drug candidates, leveraging Yoon's return.
Yoon said, "In a situation where economic uncertainties continue, this is a critical time for Huons Group to leap forward," adding that he would address key tasks for sustainable future growth, such as global market expansion and securing new growth engines through research and development.
During the Huons Global shareholders' meeting that day, issues including financial statements, approval of dividends, amendments to the articles of incorporation, reduction of capital reserves, appointment of Song Soo-young as an internal director, and appointment of Han Seung-beom as an external director were all passed as proposed.
A representative of Huons Group noted, "For the past 60 years, with the support of our shareholders, our employees have united to lay the foundation for growth," and added, "We will do our utmost to present Huons Group's vision and diversify our business areas and portfolio to enhance the company's value."